Lilly falls after oral weight-loss drug data fails to impress

** Shares of drugmaker Eli Lilly LLY.N fall 10.6% to $666.25 premarket

** LLY says its oral weight loss drug, orforglipron, helped patients lose 12.4% of their body weight on average when given the highest dose of 36 milligrams in a late-stage study

** "We are disappointed in this data, and expect to see investors lash out at LLY today," Bernstein analysts said, adding that investors were expecting around 14% weight loss at the highest dose

** Danish rival Novo Nordisk's NOVOb.CO injectable weight-loss treatment Wegovy showed 14.9% weight loss over 68 weeks in a 2021 trial

** U.S.-listed shares of Novo rose 13% to $51.38 premarket

** Shares of smaller rival Viking Therapeutics VKTX.O, which is also developing an oral weight-loss drug, rose 9.8% to $35 premarket

** Up to last close, LLY was down 3.3%, VKTX down ~21%, U.S.-listed shares of Novo down 47% YTD